Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL019 in Adult Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
NCT02167360Phase 2Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Abramson Cancer Center. Planned start Jun 2016; status: withdrawn.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02167360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167360.